Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn’s Disease: Efficacy in a Single-Centre Cohort
Open Access
- 13 April 2017
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 11 (10) , 1161-1168
Abstract
Haematopoietic stem cell transplantation [HSCT] is considered a therapeutic option for patients with severe Crohn’s disease [CD] unresponsive to currently available therapies. Autologous HSCT was considered for CD patients with active disease, unresponsive or intolerant to approved medications and unsuitable for surgery. After HSCT, patients were closely followed up every 6 weeks during the first 2 years and every 6 months thereafter up to 5 years. Colonoscopy and/or magnetic resonance imaging were performed at Months 6, 12, 24, and 48 after HSCT. From December 1, 2007 to December 31, 2015, 37 CD patients were assessed for HSCT. Of these, 35 patients [13 within the ASTIC trial] underwent mobilisation. Six patients did not complete the transplant for various reasons and 29 patients were finally transplanted. Patients were followed up during a median of 12 months [6–60]. At 6 months, 70% of patients achieved drug-free clinical remission (Crohn’s Disease Index of Severity [CDAI] < 150). The proportion of patients in drug-free remission (CDAI < 150, Simple Endoscopic activity Score [SES]-CD < 7] was 61% at 1 year, 52% at 2 years, 47% at 3 years, 39% at 4 years, and 15% at 5 years. Patients who relapsed were re-treated and 80% regained clinical remission. Six out of the 29 [21%] required surgery. One patient died due to systemic cytomegalovirus infection 2 months after transplant. HSCT is a salvage therapy for patients with extensive and refractory CD. Although relapse occurs in a majority of patients within 5 years after transplant, drug responsiveness is regained and clinical remission achieved in 80% of cases.Keywords
Funding Information
- Ministerio de Economía y Competitividad
This publication has 23 references indexed in Scilit:
- Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation ResearchHaematologica, 2012
- Remission of refractory Crohn's disease by high‐dose cyclophosphamide and autologous peripheral blood stem cell transplantationAlimentary Pharmacology & Therapeutics, 2012
- Loss of Interleukin-10 Signaling and Infantile Inflammatory Bowel Disease: Implications for Diagnosis and TherapyGastroenterology, 2012
- Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 ReceptorNew England Journal of Medicine, 2009
- Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune DiseasesHaematologica, 2009
- Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn’s diseaseGut, 2007
- Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s diseaseGastroenterology, 2005
- Complete Clinical Remission after High-Dose Immune Suppression and Autologous Hematopoietic Stem Cell Transplantation in Severe Crohn’s Disease Refractory to Immunosuppressive and Immunomodulator TherapyInflammatory Bowel Diseases, 2004
- Hematopoietic stem cell transplantation for severe Crohn's diseaseBone Marrow Transplantation, 2003
- Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantationBone Marrow Transplantation, 2003